Navigation Links
Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Date:9/25/2007

ectly by individual shareholders or small banks," said James A. Bianco, M.D., President and CEO of CTI. "I'd also like to thank our shareholders who attended the meeting."

During management's presentation, Bianco introduced CTI's strategic platform, which is intended to reduce the risk of current and future cancer drug development. He also reviewed CTI's growth through acquisition initiative, which resulted in the recent acquisition of Systems Medicine and Brostallicin as well as the agreement to acquire Zevalin(R) (ibritumomab tiuxetan) from Biogen IDEC, which is pending closing. Bianco outlined CTI's development plans and upcoming milestones for its pipeline, including XYOTAX(TM) (paclitaxel poliglumex, CT-2103), pixantrone (BBR 2778), and Brostallicin.

"As a result of our recent acquisitions and with our existing pipeline, we have built a powerful, diversified oncology pipeline. This gives us the potential for multiple pivotal and regulatory milestones in 2008 and 2009. We are integrating several components of our strategy, ranging from developing next generation versions of proven effective agents to using cutting edge genomic science to target the right patients for the right drug, which we believe will allow us to manage the risk inherent in cancer drug development," noted Bianco.

"While we anticipate our 2007 net loss to be consistent with the 2006 net loss, we will need to raise additional capital to move our programs forward over the next few years. If we achieve our product pipeline, acquisition, and sales targets, our goal is to break even in 2009 and have a profitable operating company by 2010," Bianco added. For more information on CTI's strategy and development pipeline or to see the archived presentation, please visit our Web site at http://www.cticseattle.com.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to deve
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
(Date:9/30/2014)... Applying a well-known optical phenomenon called thin-film interference, ... demonstrated the ability to "paint" ultra-thin coatings onto ... for making future, flexible electronic devices, creating advanced ... rocket ships and spacecraft with extremely lightweight decorative ... water, it becomes iridescent, revealing a myriad of ...
(Date:9/30/2014)... of one of nature,s most efficient light-harvesting structures, ... by Alejandro Briseno of the University of Massachusetts ... long-sought polymer architecture to boost power-conversion efficiency of ... , Briseno, with colleagues and graduate students ... and Dresden University of Technology, Germany, report in ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... scientists observe a reaction moving at greater than 10 meters ... feat some would say is nearly impossible. But ... dynamic transmission electron microscope (DTEM). DTEM,s ability to ... it,s happening has earned it one of the 10 winning ...
... , Aug. 2 Octapharma USA today ... is the Rush Hemophilia & Thrombophilia Center at Rush ... focused on human protein therapies in hematology, immune therapy, intensive care and emergency ... Leonard A. ...
... Aug. 2 Tengion Inc. (Nasdaq: TNGN ... to the position of Chief Financial Officer.  Mr. Davis comes to Tengion ... technologies to develop improved protein therapeutics. At its peak, Neose employed 200 ... , , ...
Cached Biology Technology:Livermore's DTEM earns innovation award from Microscopy Today 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6Tengion Appoints A. Brian Davis Chief Financial Officer 2
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... Smart Search & Match,the leading provider of high-performance ... has joined the company as Product Marketing Manager. ... 15 years of product and marketing management,experience to ... many high-tech products and solutions worldwide. He has ...
... the human body in ways never imagined only a ... population of patients who are newly susceptible to opportunistic ... formidable clinical opponent, and foremost among them is ... from ASM Press. "This volume has been ...
... of the global population living in cities reached 50 ... exciting new book series which brings together leading experts ... all over the world. The aim of the ... facing the architects, planners, developers and inhabitants of the ...
Cached Biology News:New text focuses on formidable opportunistic fungus 2Springer looks ahead to the Future City 2
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Peptide-affinity Purified Polyclonal Antibody to MTR...
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Polyclonal Antibody to PRG3...
Biology Products: